The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
Ongoing Research Aims to Expand Treatment Options, Address Unmet Needs in GVHD
FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer